Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jan 15, 2026; 17(1): 114210
Published online Jan 15, 2026. doi: 10.4239/wjd.v17.i1.114210
Published online Jan 15, 2026. doi: 10.4239/wjd.v17.i1.114210
Commentary on α-1-microglobulin as a predictor of diabetic complications
Li Liao, An Luo, Long-Han Zhang, Yi-Ting Pan, Ya-Qing Liu, School of Nursing, University of South China, Hengyang 421001, Hunan Province, China
Author contributions: Liao L and Luo A conceived the study and drafted the manuscript; Zhang LH, Pan YT and Liu YQ contributed to critical review, editing, and intellectual revision of the content; all authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest related to this manuscript.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li Liao, PhD, School of Nursing, University of South China, No. 28 West Changsheng Road, Hengyang 421001, Hunan Province, China. 254251558@qq.com
Received: September 15, 2025
Revised: October 25, 2025
Accepted: November 19, 2025
Published online: January 15, 2026
Processing time: 122 Days and 18.2 Hours
Revised: October 25, 2025
Accepted: November 19, 2025
Published online: January 15, 2026
Processing time: 122 Days and 18.2 Hours
Core Tip
Core Tip: This letter comments on the recent study regarding serum α1-microglobulin (α1-MG) as a predictor of multiple complications in type 2 diabetes mellitus. The letter underscores the importance of α1-MG as a potential biomarker linking renal, retinal, neural, and cardiac complications, and highlights the need for multi-center validation and cost-effectiveness evaluation before clinical adoption.